GLP-1 Receptor Agonists and Kidney Outcomes: Meta-analysis of Cardiovascular Outcome Trials
glp1 · Lancet Diabetes & Endocrinology · 2021
Across 8 trials and 60,080 participants, GLP-1 agonists reduced kidney composite outcomes by 21% and slowed eGFR decline.
Authors
Sattar N, Lee MMY, Kristensen SL, et al.
Research lens
Across 8 trials and 60,080 participants, GLP-1 agonists reduced kidney composite outcomes by 21% and slowed eGFR decline.
- glp1
- kidney
- meta-analysis
- inflammation